| TiterZyme® Kits
(ELISA Kits) |
|
 |
| XIAP
TiterZyme® (EIA) Kit |
| Assay Format |
Catalog # |
Kit Insert |
MSDS |
Assay Layout |
| human: 96 Well Kit |
900-124 |
|
|
|
|
 |

FOR RESEARCH PURPOSES ONLY, NOT FOR DIAGNOSTIC USE. |

|

Stable, Liquid Color-Coded Reagents
Time to Answer: 3 Hours
|
 
XIAP (X-linked Inhibitor of Apoptosis) is known by a variety of other
names (baculoviral IAP repeat containing protein 4 (BIRC4), mammalian
IAP homolog A (MIHA), X-linked inhibitor of apoptosis protein 3,
X-linked IAP, HILP, IAP Like protein and ILP). XIAP belongs to the IAP (inhibitors
of apoptosis) family, which is characterized by one or more BIR (baculovirus
IAP repeat) domains. These proteins have multiple biological functions
that include binding and inhibiting caspases, regulating cell cycle
progression and modulating receptor-mediated signal transduction. XIAP
is a broad-ranging suppressor of apoptosis and functions by direct
binding and inhibition of several caspases, including
caspase-3, caspase-7 and caspase-9. There are three BIR domains in
XIAP: BIR1, BIR2 and BIR3. BIR2 has been implicated in the binding and
inhibition of
caspase-3 and caspase-7 and BIR3 has been reported to be a specific
inhibitor of caspase-9.
|

|

|

1. Pipet Standards and Samples in duplicate into the wells and incubate.
2. Aspirate and wash the plate.
3. Pipet the yellow Antibody into the wells and incubate.
4. Aspirate and wash the plate.
5. Pipet the blue Conjugate into the wells and incubtate.
6. Aspirate and wash the plate.
7. Pipet Substrate into the wells and incubate.
8. Pipet Stop solution and read plate on a plate reader at 450nm.
9. Calculate sample concentrations from the Standard Curve.
|

| |
human XIAP
(900-124) |
| RANGE |
312.5 - 10,000 pg/mL
|
| SAMPLE SIZE |
100 µL |
| SAMPLES PER 96
WELL KIT |
40 in duplicate |
| SENSITIVITY |
90.6 pg/mL |
| PRECISION |
2.6-15.1% Intra
6.0-13.4% Inter |
SAMPLE TYPE
recommended dilution |
0.5 million HeLa
cells/mL ( 1:2)
|
| TIME TO ANSWER |
3 Hours |
| SPECIES
SPECIFICITY |
human |
|

| Compound |
Cross Reactivity |
Compound |
Cross Reactivity |
| human XIAP |
100% |
Survivin |
3.2% |
| <0.1%: cIAP-1
/ Caspase-3 / Smac/DIABLO |
|